Role of Vascular Endothelial Markers in Predicting Renal Prognosis and Mortality in Patients Undergoing HD-AKI

NCT07637435 | Completed DMC

• 1 other identifier: 25/22
• Study Type: interventional
• Target: 170
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study was to evaluate the role of Activin A, Nostrin, and Angiopoetin-2 levels in predicting the prognosis of renal function and in-hospital and 6-month mortality in patients undergoing emergency hemodialysis treatment for acute kidney injury. The main questions it aims to answer are: Acute renal injury is a clinical entity with very important consequences. Mortality and morbidity are high in patients requiring hemodialysis. This study aims to evaluate the predictive effects of certain biomarkers on outcomes such as short- and long-term monitoring of renal function, weaning or continuation of hemodialysis, in-hospital and 6-month mortality in these patients. In patients with an indication for emergency hemodialysis, the following levels will be measured before hemodialysis:

• Serum Activin A,
• Serum Nostrin,
• Serum Angiopoetin-2

Conditions

Acute Kidney Injury; Hemodialysis

Keywords

Activin A; Nostrin; Angiopoetin-2; Acute kidney injury; Hemodialysis

Outcome Measures

Primary Outcomes (1)

• Correlation of serum nostrin, activin A, angiopoetin-2 levels and in-hospital clinical results and outcomes (mortality, weaning from HD)

  Up to 3 months were sufficient for patient recruitment for the study. After patient recruitment was completed, the investigators followed the patients during their in-hospital days monitoring their need for hemodialysis and survival/death status.

  From the day of the first hemodialysis session until in-hospital death or discharge. (maximum up to 100 days)

Secondary Outcomes (1)

• All cause mortality and need for hemodialysis or weaning from hemodialysis

  180 days after the initiation of first hemodialysis session

Study Arms (1)

AKI-HD GROUP

OTHER

Acute kidney injury (undergoing hemodialysis) arm. The only group in the study. Measurement of serum Activin A, serum Nostrin, serum Angiopoetin-2

Diagnostic Test: Serum samples before hemodialysis.

Interventions

Serum samples before hemodialysis. DIAGNOSTIC_TEST

Except from taking a venous blood sample there are no interventions.

AKI-HD GROUP

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients 18 years and older of age requiring hemodialysis for acute kidney injury

You may not qualify if:

• Patients under 18 years of age
• Patients under chronic renal replacement therapy
• Patients with a history of renal transplantation

Sponsors & Collaborators

• Muğla Sıtkı Koçman University: lead

Study Sites (1)

Mugla Sitki Kocman University

Muğla, Menteşe, 48000, Turkey (Türkiye)

Location

Related Publications (3)

• Erfurt S, Lauxmann M, Asmus K, Oess S, Patschan D, Hoffmeister M. Serum Nostrin-A risk factor of death, kidney replacement therapy and acute kidney disease in acute kidney injury. PLoS One. 2024 Apr 11;19(4):e0299131. doi: 10.1371/journal.pone.0299131. eCollection 2024.

  PMID: 38603667 BACKGROUND

• Kovacevic I, Hu J, Siehoff-Icking A, Opitz N, Griffin A, Perkins AC, Munn AL, Muller-Esterl W, Popp R, Fleming I, Jungblut B, Hoffmeister M, Oess S. The F-BAR protein NOSTRIN participates in FGF signal transduction and vascular development. EMBO J. 2012 Aug 1;31(15):3309-22. doi: 10.1038/emboj.2012.176. Epub 2012 Jun 29.

  PMID: 22751148 BACKGROUND

• Robinson-Cohen C, Katz R, Price BL, Harju-Baker S, Mikacenic C, Himmelfarb J, Liles WC, Wurfel MM. Association of markers of endothelial dysregulation Ang1 and Ang2 with acute kidney injury in critically ill patients. Crit Care. 2016 Jul 3;20(1):207. doi: 10.1186/s13054-016-1385-3.

  PMID: 27372077 BACKGROUND

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Officials

• Alper Alp, Assoc Prof,MD

  Muğla Sıtkı Koçman University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Professor, MD

Study Record Dates

• First Submitted: May 7, 2026
• First Posted: June 9, 2026
• Study Start: February 21, 2025
• Primary Completion: May 15, 2025
• Study Completion: December 15, 2025
• Last Updated: June 11, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)